{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T01:02:39Z","timestamp":1773104559692,"version":"3.50.1"},"reference-count":92,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p><jats:italic>Schistosoma haematobium<\/jats:italic>, the causative agent of urogenital schistosomiasis, is a carcinogen type 1 since 1994. It is strongly associated with bladder squamous-cell carcinoma in endemic regions, where it accounts for 53-69% of bladder-carcinoma cases. This histological subtype is associated with chronic inflammation being more aggressive and resistant to conventional chemo and radiotherapy. Immune-Checkpoint-Blockage (ICB) therapies targeting the Programmed-Cell-Death-Protein-1(PD-1)\/Programmed-Cell-Death-Ligand-1(PD-L1) axis showed considerable success in treating advanced bladder urothelial carcinoma. PD-L1 is induced by inflammatory stimuli and expressed in immune and tumor cells. The binding of PD-L1 with PD-1 modulates immune response leading to T-cell exhaustion. PD-L1 presents in several isoforms and its expression is dynamic and can serve as a companion marker for patients\u2019 eligibility, allowing the identification of positive tumors that are more likely to respond to ICB therapy. The high PD-L1 expression in bladder-urothelial-carcinoma and squamous-cell carcinoma may affect further ICB-therapy application and outcomes. In general, divergent histologies are ineligible for therapy. These treatments are expensive and prone to auto-immune side effects and resistance. Thus,  biomarkers capable of predicting therapy response are needed. Also, the PD-L1 expression assessment still needs refinement. Studies focused on squamous cell differentiation associated with <jats:italic>S. haematobium<\/jats:italic> remain scarce. Furthermore, in low and middle-income-regions, where schistosomiasis is endemic, SCC biomarkers are needed. This mini-review provides an overview of the current literature regarding PD-L1 expression in bladder-squamous-cell-carcinoma and schistosomiasis. It aims to pinpoint future directions, controversies, challenges, and the importance of PD-L1 as a biomarker for diagnosis, disease aggressiveness, and ICB-therapy prognosis in bladder-schistosomal-squamous-cell carcinoma.<\/jats:p>","DOI":"10.3389\/fimmu.2022.955000","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T10:28:05Z","timestamp":1662114485000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Programmed Cell Death-Ligand-1 expression in Bladder Schistosomal Squamous Cell Carcinoma \u2013 There\u2019s room for Immune Checkpoint Blockage?"],"prefix":"10.3389","volume":"13","author":[{"given":"Ana C.","family":"Madureira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"key":"B1","volume-title":"Schistosomiasis","year":"2022"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61949-2","article-title":"Human schistosomiasis","volume":"383","author":"Colley","year":"2014","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/pim.12087","article-title":"Immunology of human schistosomiasis","volume":"36","author":"Colley","year":"2014","journal-title":"Parasit Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00089","article-title":"The schistosoma granuloma: friend or foe","volume":"4","author":"Hams","year":"2013","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1096\/fj.14-259572","article-title":"Macrophages are required for host survival in experimental urogenital schistosomiasis","volume":"29","author":"Fu","year":"2015","journal-title":"FASEB J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002605","article-title":"A novel mouse model of schistosoma haematobium egg-induced immunopathology","volume":"8","author":"Fu","year":"2012","journal-title":"PloS Pathog"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis524","article-title":"Integrated analysis of innate, Th1, Th2, Th17, and regulatory cytokines identifies changes in immune polarisation following treatment of human schistosomiasis","volume":"208","author":"Bourke","year":"2013","journal-title":"J Infect Dis"},{"key":"B8","volume-title":"IARC monographs on the evaluation of carcinogenic risks to humans","year":"1994"},{"key":"B9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.4103\/aam.aam_48_17","article-title":"A review of bladder cancer in Sub-Saharan Africa: A different disease, with a distinct presentation, assessment, and treatment","volume":"17","author":"Bowa","year":"2018","journal-title":"Ann Afr Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.aju.2016.07.001","article-title":"Squamous cell carcinoma of the urinary bladder: Systematic review of clinical characteristics and therapeutic approaches","volume":"14","author":"Martin","year":"2016","journal-title":"Arab J Urol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4111\/icu.2018.59.5.285","article-title":"Immune checkpoint inhibitors for urothelial carcinoma","volume":"59","author":"Kim","year":"2018","journal-title":"Investig Clin Urol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18563","article-title":"Squamous differentiation in pT1 bladder urothelial carcinoma predicts poor response for intravesical chemotherapy","volume":"9","author":"Li","year":"2018","journal-title":"Oncotarget"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2019.01.020","article-title":"The impact of squamous histology on survival in patients with muscle-invasive bladder cancer","volume":"37","author":"Matulay","year":"2019","journal-title":"Urol Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-019-01409-x","article-title":"Squamous cell carcinoma of the bladder: poor response to neoadjuvant chemotherapy","volume":"24","author":"Dotson","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ctro.2018.12.001","article-title":"A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the national cancer database","volume":"15","author":"Fischer-Valuck","year":"2019","journal-title":"Clin Transl Radiat Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0087","article-title":"FDA Approval summary: Atezolizumab for the treatment of patients with progressive advanced urothelial carcinoma after platinum-containing chemotherapy","volume":"22","author":"Ning","year":"2017","journal-title":"Oncologist"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0084","article-title":"FDA Approval summary: Atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy","volume":"24","author":"Suzman","year":"2019","journal-title":"Oncologist"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2017.11.002","article-title":"Anti-programmed cell death 1\/Ligand 1 (PD-1\/PD-L1) antibodies for the treatment of urothelial carcinoma: State of the art and future development","volume":"16","author":"Powles","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci Transl Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13123034","article-title":"Soluble programmed death ligand-1 (sPD-L1): A pool of circulating proteins implicated in health and diseases","volume":"13","author":"Bailly","year":"2021","journal-title":"Cancers"},{"key":"B22","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1084\/jem.20180870","article-title":"Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer","volume":"216","author":"Gong","year":"2019","journal-title":"J Exp Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3747\/co.25.4031","article-title":"Harmonization of PD-L1 testing in oncology: a Canadian pathology perspective","volume":"25","author":"Ionescu","year":"2018","journal-title":"Curr Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.22551\/2021.30.0801.10179","article-title":"PD-L1 testing and immunotherapy selection - early laboratory experience and its potential role in head and neck cancer management","volume":"8","author":"Bancu","year":"2021","journal-title":"Arch Clin Cases"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001264","article-title":"PD-L1 expression in urothelial carcinoma with predominant or pure variant histology: Concordance among 3 commonly used and commercially available antibodies","volume":"43","author":"Reis","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s40425-017-0299-1","article-title":"Biomarkers for immunotherapy in bladder cancer: a moving target","volume":"5","author":"Aggen","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001084","article-title":"PD-L1 immunohistochemistry assay concordance in urothelial carcinoma of the bladder and hypopharyngeal squamous cell carcinoma","volume":"42","author":"Hodgson","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00962","article-title":"Prognostic and clinicopathological significance of PD-L1 in patients with bladder cancer: A meta-analysis","volume":"10","author":"Zhu","year":"2019","journal-title":"Front Pharmacol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/JU.0000000000000761","article-title":"Histological subtypes and response to PD-1\/PD-L1 blockade in advanced urothelial cancer: A retrospective study","volume":"204","author":"Miller","year":"2020","journal-title":"J Urol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.10.026","article-title":"Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur Urol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22690","article-title":"Regulation of PD-1\/PD-L1 pathway and resistance to PD-1\/PD-L1 blockade","volume":"8","author":"Bai","year":"2017","journal-title":"Oncotarget"},{"key":"B32","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-242493","article-title":"Early presentation of pembrolizumab-associated pneumonitis","volume":"14","author":"Christy","year":"2021","journal-title":"BMJ Case Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93754-z","article-title":"Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder","volume":"11","author":"Tosev","year":"2021","journal-title":"Sci Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-016-4997-y","article-title":"Insight into the molecular basis of schistosoma haematobium-induced bladder cancer through urine proteomics","volume":"37","author":"Bernardo","year":"2016","journal-title":"Tumour Biol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/16.5.1181","article-title":"Mutations in the p53 gene in schistosomal bladder cancer: a study of 92 tumours from Egyptian patients and a comparison between mutational spectra from schistosomal and non-schistosomal urothelial tumours","volume":"16","author":"Warren","year":"1995","journal-title":"Carcinogenesis"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0010176","article-title":"Host tissue proteomics reveal insights into the molecular basis of schistosoma haematobium-induced bladder pathology","volume":"16","author":"Osakunor","year":"2022","journal-title":"PloS Negl Trop Dis"},{"key":"B38","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3390\/diagnostics10010054","article-title":"Disabled homolog 2 (DAB2) protein in tumor microenvironment correlates with aggressive phenotype in human urothelial carcinoma of the bladder","volume":"10","author":"Itami","year":"2020","journal-title":"Diagn (Basel)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.580302","article-title":"Emerging roles of disabled homolog 2 (DAB2) in immune regulation","volume":"11","author":"Figliuolo da Paz","year":"2020","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00304","article-title":"Rapid downregulation of DAB2 by toll-like receptor activation contributes to a pro-inflammatory switch in activated dendritic cells","volume":"10","author":"Figliuolo da Paz","year":"2019","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2003.10.006","article-title":"Muscle invasive schistosomal squamous cell carcinoma of the urinary bladder: frequency and prognostic significance of p53, BCL-2, HER2\/neu, and proliferation (MIB-1)","volume":"35","author":"Badr","year":"2004","journal-title":"Hum Pathol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)66332-X","article-title":"Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, e-cadherin, epidermal growth factor receptor and c-erbB-2","volume":"165","author":"Haitel","year":"2001","journal-title":"J Urol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09854.x","article-title":"Bilharzial vs non-bilharzial related bladder cancer: pathological characteristics and value of cyclooxygenase-2 expression","volume":"108","author":"Youssef","year":"2011","journal-title":"BJU Int"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.08.109","article-title":"Utility of biomarkers in the prediction of oncologic outcome after radical cystectomy for squamous cell carcinoma","volume":"193","author":"Youssef","year":"2015","journal-title":"J Urol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1750-9378-8-9","article-title":"Immunohistochemical expression of COX2 and iNOS in bladder cancer and its association with urinary schistosomiasis among Sudanese patients","volume":"8","author":"Hassan","year":"2013","journal-title":"Infect Agent Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2014.09.020","article-title":"Role of fibroblast growth factor in squamous cell carcinoma of the bladder: prognostic biomarker and potential therapeutic target","volume":"33","author":"Youssef","year":"2015","journal-title":"Urol Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/sigtrans.2016.45","article-title":"Analyses of publicly available genomics resources define FGF-2-expressing bladder carcinomas as EMT-prone, proliferative tumors with low mutation rates and high expression of CTLA-4, PD-1 and PD-L1","volume":"2","author":"McNiel","year":"2017","journal-title":"Signal Transduct Target Ther"},{"key":"B48","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12916-021-02031-3","article-title":"Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy","volume":"19","author":"Long","year":"2021","journal-title":"BMC Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2020.04.005","article-title":"Can patients with muscle-invasive bladder cancer and fibroblast growth factor receptor-3 alterations still be considered for neoadjuvant pembrolizumab? a comprehensive assessment from the updated results of the PURE-01 study","volume":"4","author":"Necchi","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"153364","DOI":"10.1016\/j.prp.2021.153364","article-title":"Squamous differentiation is a potential biomarker predicting tumor progression in patients treated with pembrolizumab for urothelial carcinoma","volume":"219","author":"Miyama","year":"2021","journal-title":"Pathol Res Pract"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.527385","article-title":"PD-L1 expression in muscle-invasive urinary bladder urothelial carcinoma according to Basal\/Squamous-like phenotype","volume":"10","author":"Kim","year":"2020","journal-title":"Front Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1080\/15321819.2020.1845726","article-title":"Stratification of urinary bladder carcinoma based on immunohistochemical expression of CK5, CK14 and CK20","volume":"42","author":"Al-Sharaky","year":"2021","journal-title":"J Immunoassay Immunochem"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1080\/15321819.2021.1937212","article-title":"Stratification of urothelial bladder carcinoma depending on immunohistochemical expression of GATA3 and CK5\/6","volume":"42","author":"Serag Eldien","year":"2021","journal-title":"J Immunoassay Immunochem"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.2.1240","article-title":"Schistosoma mansoni worms induce anergy of T cells via selective up-regulation of programmed death ligand 1 on macrophages","volume":"173","author":"Smith","year":"2004","journal-title":"J Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0124089","article-title":"Schistosoma mansoni soluble egg antigens induce expression of the negative regulators SOCS1 and SHP1 in human dendritic cells via interaction with the mannose receptor","volume":"10","author":"Klaver","year":"2015","journal-title":"PloS One"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02510","article-title":"Early induction of human regulatory dermal antigen presenting cells by skin-penetrating schistosoma mansoni cercariae","volume":"9","author":"Winkel","year":"2018","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1080\/20013078.2020.1753420","article-title":"DC-SIGN mediated internalisation of glycosylated extracellular vesicles from schistosoma mansoni increases activation of monocyte-derived dendritic cells","volume":"9","author":"Kuipers","year":"2020","journal-title":"J Extracell Vesicles"},{"key":"B58","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nri843","article-title":"The immunobiology of schistosomiasis","volume":"2","author":"Pearce","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/nri1183","article-title":"Immune regulation by helminth parasites: cellular and molecular mechanisms","volume":"3","author":"Maizels","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13071-020-04015-3","article-title":"B cells induced by schistosoma japonicum infection display diverse regulatory phenotypes and modulate CD4(+) T cell response","volume":"13","author":"Xiao","year":"2020","journal-title":"Parasit Vectors"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082480","article-title":"TLR2 directing PD-L2 expression inhibit T cells response in schistosoma japonicum infection","volume":"8","author":"Gao","year":"2013","journal-title":"PloS One"},{"key":"B62","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1186\/s13071-021-05006-8","article-title":"Granulocytic myeloid-derived suppressor cells inhibit T follicular helper cells during experimental schistosoma japonicum infection","volume":"14","author":"Zhang","year":"2021","journal-title":"Parasit Vectors"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/pim.12602","article-title":"Schistosoma haematobium cercarial infection alters subsequent systemic immune responses to eggs but has minimal impact on immune responses to egg injection of the bladder","volume":"41","author":"Loc","year":"2019","journal-title":"Parasit Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00669-19","article-title":"Interleukin-4 signaling plays a major role in urogenital schistosomiasis-associated bladder pathogenesis","volume":"88","author":"Mbanefo","year":"2020","journal-title":"Infect Immun"},{"key":"B65","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1750-9378-9-21","article-title":"Impact of density of schistosomal antigen expression in urinary bladder tissue on the stratification, cell type, and staging, and prognosis of carcinoma of the bladder in Egyptian patients","volume":"9","author":"Wishahi","year":"2014","journal-title":"Infect Agent Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19913","article-title":"PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy","volume":"8","author":"Pichler","year":"2017","journal-title":"Oncotarget"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2018.06.028","article-title":"PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases","volume":"81","author":"Davick","year":"2018","journal-title":"Hum Pathol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.06.019","article-title":"Frequent PD-L1 protein expression and molecular correlates in urinary bladder squamous cell carcinoma","volume":"74","author":"Udager","year":"2018","journal-title":"Eur Urol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2019.02.017","article-title":"Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder","volume":"37","author":"Owyong","year":"2019","journal-title":"Urol Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12885-020-06727-2","article-title":"Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation","volume":"20","author":"Morsch","year":"2020","journal-title":"BMC Cancer"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.21037\/tau.2020.02.12","article-title":"Expression and prognostic value of PD-L1 in non-schistosoma-associated urinary bladder squamous cell carcinoma","volume":"9","author":"Liu","year":"2020","journal-title":"Transl Androl Urol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2020.151640","article-title":"Increased PD-L1 expression in high-grade bladder cancer with squamous cell differentiation in Bulgarian and French patients\u2019 samples","volume":"49","author":"Gulinac","year":"2020","journal-title":"Ann Diagn Pathol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1177\/10668969211027264","article-title":"The significance of squamous histology on clinical outcomes and PD-L1 expression in bladder cancer","volume":"30","author":"Gordetsky","year":"2021","journal-title":"Int J Surg Pathol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S291327","article-title":"Prognostic value of programmed death ligand-1 expression on tumor-infiltrating immune cells in patients treated with cisplatin-based combination adjuvant chemotherapy following radical cystectomy for muscle-invasive bladder cancer: A retrospective cohort study","volume":"14","author":"Lee","year":"2021","journal-title":"Onco Targets Ther"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000128","article-title":"Complete response to anti-PD-L1 antibody in a metastatic bladder cancer associated with novel MSH4 mutation and microsatellite instability","volume":"8","author":"Yang","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.01.003","article-title":"Comprehensive assessment of immuno-oncology biomarkers in adenocarcinoma, urothelial carcinoma, and squamous-cell carcinoma of the bladder","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur Urol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.3390\/cancers13112548","article-title":"High serum PD-L1 levels are associated with poor survival in urothelial cancer patients treated with chemotherapy and immune checkpoint inhibitor therapy","volume":"13","author":"Krafft","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13716","article-title":"Plasma levels of soluble PD-L1 correlate with tumor regression in patients with lung and gastric cancer treated with immune checkpoint inhibitors","volume":"39","author":"Ando","year":"2019","journal-title":"Anticancer Res"},{"key":"B79","doi-asserted-by":"publisher","first-page":"5841","DOI":"10.3390\/cancers13225841","article-title":"Soluble PD-L1 in serum and urine in urinary bladder cancer patients","volume":"13","author":"Vikerfors","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2018.05.015","article-title":"Prognostic value of testing PD-L1 expression after radical cystectomy in high-risk patients","volume":"16","author":"Pichler","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-99311-y","article-title":"Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment","volume":"11","author":"Oh","year":"2021","journal-title":"Sci Rep"},{"key":"B82","doi-asserted-by":"publisher","first-page":"764","DOI":"10.3390\/jcm10040764","article-title":"Expression of ADAM proteases in bladder cancer patients with BCG failure: A pilot study","volume":"10","author":"Pichler","year":"2021","journal-title":"J Clin Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.12247","article-title":"Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics","volume":"6","author":"Zhang","year":"2015","journal-title":"Thorac Cancer"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0329","article-title":"Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade","volume":"5","author":"Zhou","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.626932","article-title":"The prognostic value of circulating soluble programmed death ligand-1 in cancers: A meta-analysis","volume":"10","author":"Huang","year":"2020","journal-title":"Front Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/7912186","article-title":"Cytological and wet mount microscopic observations made in urine of schistosoma haematobium-infected children: Hint of the implication in bladder cancer","volume":"2019","author":"Tetteh-Quarcoo","year":"2019","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/medsci10010014","article-title":"Dynamics in morbidity markers and cytological observations made in urine of schistosoma haematobium-infected children: Pre- and post-praziquantel treatment in an endemic setting","volume":"10","author":"Tetteh-Quarcoo","year":"2022","journal-title":"Med Sci (Basel)"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1086\/425579","article-title":"Increased ratio of tumor necrosis factor-alpha to interleukin-10 production is associated with schistosoma haematobium-induced urinary-tract morbidity","volume":"190","author":"Wamachi","year":"2004","journal-title":"J Infect Dis"},{"key":"B89","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1186\/1471-2334-14-501","article-title":"Urinary cytokines in schistosoma haematobium-infected schoolchildren from tana delta district of Kenya","volume":"14","author":"Njaanake","year":"2014","journal-title":"BMC Infect Dis"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.14-0444","article-title":"Age-stratified profiles of serum IL-6, IL-10, and TNF-alpha cytokines among Kenyan children with schistosoma haematobium, plasmodium falciparum, and other chronic parasitic Co-infections","volume":"92","author":"Bustinduy","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-6706-0","article-title":"Predictive value of CD44 in muscle-invasive bladder cancer and its relationship with IL-6 signaling","volume":"25","author":"Wu","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.canlet.2020.06.018","article-title":"Targeting Stat3 signaling impairs the progression of bladder cancer in a mouse model","volume":"490","author":"Korac-Prlic","year":"2020","journal-title":"Cancer Lett"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.955000\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T11:25:00Z","timestamp":1662463500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.955000\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":92,"alternative-id":["10.3389\/fimmu.2022.955000"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.955000","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,2]]},"article-number":"955000"}}